Updates are available Correction dated 2024-11-26
Click to view Correction: https://doi.org/10.1038/s41573-024-01103-2
-
Authors
Lee, Dennis S. W.
Rojas, Olga L. https://orcid.org/0000-0003-2300-1658
Gommerman, Jennifer L. https://orcid.org/0000-0003-4576-6168
- License Information
-
More Information
Article History
Accepted: 26 October 2020
First Online: 15 December 2020
Change Date: 26 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41573-024-01103-2
Competing interests
: J.L.G. performed consulting for Roche on anti-CD20 in multiple sclerosis in 2019 and received funding for research on the impact of anti-CD20 in experimental autoimmune encephalomyelitis (Roche) and sphingosine 1-phosphate receptor 1 inhibitors in experimental autoimmune encephalomyelitis (Novartis). These interests did not influence the content of this Review. The other authors declare no competing interests.
